Posted on February 29, 2008 at 12:17 PM
Filed under: Acquisitions
Tagged: Abraxis BioScience , Actavis Group , Barr Pharmaceuticals , Christopher Begley , earnings , Hospira , M&A , Mayne Pharma , Merck , Novartis , Teva Pharmaceutical

[ Share ]  [ E-mail ]  [ Leave a Comment ]

Hospira Inc. CEO Christopher Begley said in a statement in September 2006 that the $2.1 billion purchase of Australian generic cancer drugs group Mayne Pharma Ltd. would add to Hospira's earnings per share in 2007. Lo and behold, the company just reported a 60% jump in fourth-quarter net income. No wonder companies such as Israel's Teva Pharmaceutical Industries Ltd. and Swiss group Novartis AG were thought to have been interested in Mayne as well, as The Deal's Giles Parkinson wrote. The purchase made Lake Forest, Ill.-based Hospira the largest global provider of injectable drugs to hospitals. Hospira expects net sales growth for 2008 to be approximately 6% to 8%.  - Baz Hiralal

Go to the story from chicagotribune.com


Join Corporate Dealmaker's LinkedIn forum

Also From Corporate Dealmaker

• GM revamps Opel management for restructuring
• Linklaters' Schmidt on Pfizer-Wyeth review
• Exxon has a JV in what?
• JAL talks with Delta, American heat up
• Storm clouds over CVS Caremark

Corporate Dealmaker Home Page

From TheDeal.com

• Citigroup still pays for ex-CEO's current assistant
• Deal Stocks: C, BAC, BX, T, H, ACOM, GS
• Linklaters' Schmidt on Pfizer-Wyeth review
• Rebranding Citi Alternatives would be a waste
• Blackstone buys into Glimcher malls

TheDeal.com Home

Post a comment

Name:

Email Address:

URL:

Remember personal info?

Comments: (you may use HTML tags for style)

Please only click "Post" once. It may take a few moments to process.